NCT02184520终止不适用
A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Fusion Rates
研究概览
简要总结
This postmarket surveillance study is being conducted to evaluate the TRANSITION Stabilization System as an adjunct to fusion in the treatment of acute or chronic instabilities or deformities of the thoracic, lumbar and sacral spine. The study will involve up to 360 subjects at no more than 20 sites, to be treated with the TRANSITION Stabilization System. The data from this postmarket surveillance study will be provided to FDA in accordance with the 522 order.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any of the following acute or chronic instabilities or deformities of the thoracic, lumbar or sacral spine:
- •degenerative spondylolisthesis with objective evidence of neurologic impairment,
- •kyphosis, or
- •pseudoarthrosis (failed previous fusion)
- •Age 18 or older at the time of consent
- •Able to understand and sign informed consent form
- •Psychosocially, mentally and physically able to comply with protocol
- •Able to meet the proposed follow-up schedule at 6 mo, 12 mo, and 24 mo
排除标准
- •Prior fusion surgery or another spinal device implanted in the thoracic, lumbar or sacral spine
- •Requires treatment of more than two vertebral levels
- •Lytic spondylolisthesis at the index level(s)
- •Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
- •Sustained pathologic fractures of the spine or hip, including prior fracture or trauma to vertebral structures at any thoracic, lumbar, or sacral level
- •Morbid obesity defined as a body mass index > 40, or a weight more than 100 lbs over ideal body weight
- •Pregnant or interested in becoming pregnant within the next 2 years
- •Active systemic or local infection
- •Known allergy to device materials titanium, polycarbonate (PCU), polyethylene terepthalate (PET), or hydroxyapatite (HA).
- •Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids, excluding routine NSAIDs)
- •Systemic disease including AIDS, HIV, Hepatitis C
- •Has an active malignancy defined as a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years
- •Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc.
- •Participation in an investigational device or drug clinical trials within 30 days of surgery
- •Acute mental illness or substance abuse
- •Prisoners
结局指标
主要结局
Fusion Rates
时间窗: 24 months
The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effect of the TENA SmartCare Change Indicator on Care Efficiency and Skin Health in Long Term Care FacilitiesUrinary IncontinenceNCT05247047Essity Hygiene and Health AB108
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164
已完成
不适用
Prospective Observational Study for the Evaluation of VEOFIX Varisation StaplesHallux ValgusNCT05523219Societe dEtude, de Recherche et de Fabrication81
进行中（未招募）
不适用
Avenir® Cemented Hip Stem - PMCFPrimary OsteoarthritisPost-Traumatic Osteoarthritis of HipFemoral Neck FracturesFemoral Head NecrosisSequelae From Previous Hip SurgeryOsteotomiesCongenital Hip DysplasiaNCT03396224Zimmer Biomet100
已完成
4 期
Post-Market Surveillance Study of the TM Ardis Interbody Fusion SystemDegenerative Disc DiseaseNCT02429908Zimmer Biomet80